Glimcloud-M2-1000 SR Tablet is a fixed-dose combination medication containing Glimepiride 2 mg and Metformin 1000 mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The sustained-release formulation ensures a gradual release of Metformin, minimizing gastrointestinal side effects commonly associated with immediate-release forms and improving patient compliance. Glimcloud-M2-1000 SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor renal function prior to and during therapy, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. This combination therapy should be used under medical supervision with regular monitoring of blood glucose levels to adjust dosage and prevent complications. Glimcloud-M2-1000 SR offers an effective option for comprehensive management of hyperglycemia in type 2 diabetes.